Hutchison China MediTech Limited (Chi-Med) is a China-based, globally-focused healthcare group. The Company researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures markets and distributes prescription drugs and consumer health products in China.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Alternative Medicine
- Sub-Industry: N/A
- Symbol: LON:HCM
- CUSIP: N/A
- Web: www.chi-med.com/
- Market Cap: £2.24 billion
- Outstanding Shares: 60,681,000
- 50 Day Moving Avg: £135.43
- 200 Day Moving Avg: GBX 5,886.14
- 52 Week Range: GBX 1,785 - GBX 4,050
Sales & Book Value:
- Trailing P/E Ratio: 174.06
- P/E Growth: 0.00
- Annual Revenue: £238.15 million
- Price / Sales: 9.40
- Book Value: GBX 3.12 per share
- Price / Book: 11.83
- EBIDTA: ($44,320,000.00)
- Net Margins: 2.91%
- Return on Equity: 1.80%
- Return on Assets: 2.14%
- Average Volume: 9,532 shs.
Frequently Asked Questions for Hutchison China MediTech Limited (LON:HCM)
What is Hutchison China MediTech Limited's stock symbol?
Hutchison China MediTech Limited trades on the London Stock Exchange (LON) under the ticker symbol "HCM."
Where is Hutchison China MediTech Limited's stock going? Where will Hutchison China MediTech Limited's stock price be in 2017?
2 analysts have issued 12-month price targets for Hutchison China MediTech Limited's stock. Their forecasts range from GBX 3,840 to GBX 3,840. On average, they anticipate Hutchison China MediTech Limited's share price to reach GBX 3,840 in the next year. View Analyst Ratings for Hutchison China MediTech Limited.
Who are some of Hutchison China MediTech Limited's key competitors?
Some companies that are related to Hutchison China MediTech Limited include Taro Pharmaceutical Industries (TARO), Puma Biotechnology (PBYI), WuXi PharmaTech (Cayman) (WX), Cotiviti Holdings (COTV), Enerplus Corp (ERF), Axovant Sciences Ltd (AXON), Hikma Pharmaceuticals Plc (HIK), BTG plc (BTG), Indivior PLC (INDV), Abcam Plc (ABC), Udg Healthcare PLC (UDG), Dechra Pharmaceuticals plc (DPH), Biohaven Pharmaceutical Holding Co Ltd (BHVN), TherapeuticsMD (TXMD), TherapeuticsMD (TXMD), Genus plc (GNS), Knight Therapeutics (GUD) and Knight Therapeutics (GUD).
Who are Hutchison China MediTech Limited's key executives?
Hutchison China MediTech Limited's management team includes the folowing people:
- Simon To, Executive Chairman of the Board
- Christian Hogg, Chief Executive Officer, Executive Director
- Chig Fung Cheng, Chief Financial Officer, Executive Director
- Weiguo Su Ph.D., Executive Director
- Edith Shih, Company Secretary, Non-Executive Director
- Dan Eldar, Non-Executive Director
- Paul Rutherford Carter, Senior Independent Non-Executive Director
- Karen Jean Ferrante M.D., Non-Executive Independent Director
- Graeme Allan Jack, Independent Non-Executive Director
How do I buy Hutchison China MediTech Limited stock?
Shares of Hutchison China MediTech Limited and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Hutchison China MediTech Limited's stock price today?
MarketBeat Community Rating for Hutchison China MediTech Limited (LON HCM)MarketBeat's community ratings are surveys of what our community members think about Hutchison China MediTech Limited and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Hutchison China MediTech Limited stock can currently be purchased for approximately GBX 3,690.
Consensus Ratings for Hutchison China MediTech Limited (LON:HCM) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||2 Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||GBX 3,840|
Analysts' Ratings History for Hutchison China MediTech Limited (LON:HCM)
(Data available from 9/21/2015 forward)
|8/29/2017||Panmure Gordon||Reiterated Rating||Buy||GBX 3,840|
|8/1/2017||Beaufort Securities||Reiterated Rating||Buy|
|4/11/2016||Stifel Nicolaus||Initiated Coverage||Buy|
Earnings History for Hutchison China MediTech Limited (LON:HCM)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Hutchison China MediTech Limited (LON:HCM)
Current Year EPS Consensus Estimate: $-0.25 EPS
Dividend History for Hutchison China MediTech Limited (LON:HCM)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Hutchison China MediTech Limited (LON:HCM)Insider Trades by Quarter for Hutchison China MediTech Limited (LON:HCM)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|8/2/2017||Karen Jean Ferrante||Insider||Buy||10,000||GBX 3,475||£347,500|
|3/15/2017||Paul Rutherford Carter||Insider||Buy||2,800||GBX 2,637||£73,836|
|11/21/2016||Michael Howell||Insider||Sell||3,000||GBX 1,890||£56,700|
|10/28/2016||Michael Howell||Insider||Sell||2,500||GBX 1,860||£46,500|
|10/26/2016||Michael Howell||Insider||Sell||3,000||GBX 1,850||£55,500|
|10/25/2016||Michael Howell||Insider||Sell||1,000||GBX 1,840||£18,400|
|10/24/2016||Michael Howell||Insider||Sell||339||GBX 1,825||£6,186.75|
|10/7/2016||Michael Howell||Insider||Sell||15,000||GBX 1,790||£268,500|
|4/21/2015||Christopher Nash||Insider||Buy||1,388||GBX 1,800||£24,984|
|4/15/2015||Simon To||Insider||Buy||28,000||GBX 1,585||£443,800|
|4/10/2015||Simon To||Insider||Buy||25,000||GBX 1,421.50||£355,375|
|4/7/2015||Edith Shih||Insider||Buy||2,000||GBX 1,385||£27,700|
|4/2/2015||Simon To||Insider||Buy||10,000||GBX 1,385||£138,500|
|4/1/2015||Edith Shih||Insider||Buy||15,000||GBX 1,365||£204,750|
|3/30/2015||Edith Shih||Insider||Buy||13,000||GBX 1,300||£169,000|
Headline Trends for Hutchison China MediTech Limited (LON:HCM)
Latest Headlines for Hutchison China MediTech Limited (LON:HCM)
Hutchison China MediTech Limited (HCM) Chart for Thursday, September, 21, 2017